

# Andreas Hiester

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9609960/publications.pdf>

Version: 2024-02-01

37  
papers

814  
citations

623188

14  
h-index

500791

28  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1211  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective Randomized Trial Comparing Magnetic Resonance Imaging (MRI)-guided In-bore Biopsy to MRI-ultrasound Fusion and Transrectal Ultrasound-guided Prostate Biopsy in Patients with Prior Negative Biopsies. <i>European Urology</i> , 2015, 68, 713-720.	0.9	155
2	Prospective Evaluation of Magnetic Resonance Imaging Guided In-bore Prostate Biopsy versus Systematic Transrectal Ultrasound Guided Prostate Biopsy in Biopsy Naïve Men with Elevated Prostate Specific Antigen. <i>Journal of Urology</i> , 2014, 192, 1374-1379.	0.2	98
3	MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. <i>European Radiology</i> , 2014, 24, 2582-2589.	2.3	78
4	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020, 78, 661-669.	0.9	74
5	Feasibility of diffusional kurtosis tensor imaging in prostate MRI for the assessment of prostate cancer: Preliminary results. <i>Magnetic Resonance Imaging</i> , 2014, 32, 880-885.	1.0	52
6	The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2061-2068.	1.2	48
7	Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate. <i>Journal of Urology</i> , 2018, 199, 691-698.	0.2	38
8	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , 2020, 204, 296-302.	0.2	32
9	The PRIMETEST trial: Interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2019, 37, 507-507.	0.8	27
10	Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy—Are 2 Biopsy Cores per Magnetic Resonance Imaging Lesion Required?. <i>Journal of Urology</i> , 2018, 200, 1030-1034.	0.2	25
11	Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection. <i>Frontiers in Surgery</i> , 2018, 5, 80.	0.6	24
12	Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial. <i>World Journal of Urology</i> , 2016, 34, 215-220.	1.2	23
13	Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 441-447.	0.7	19
14	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020, 78, 779-782.	0.9	16
15	Management, Treatment, and Molecular Background of the Growing Teratoma Syndrome. <i>Urologic Clinics of North America</i> , 2019, 46, 419-427.	0.8	14
16	Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. <i>Journal of Urology</i> , 2020, 204, 1242-1248.	0.2	14
17	The PRIMETEST trial: Prospective phase II trial of primary retroperitoneal lymph node dissection (RPLND) in stage II A/B patients with seminoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 420-420.	0.8	12
18	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. <i>World Journal of Urology</i> , 2022, 40, 1505-1512.	1.2	12

#	ARTICLE	IF	CITATIONS
19	Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection – A 13-year follow-up analysis of a phase III trial cohort. <i>European Journal of Cancer</i> , 2021, 155, 64-72.	1.3	10
20	Late relapsing germ cell tumors with elevated tumor markers. <i>World Journal of Urology</i> , 2022, 40, 363-371.	1.2	6
21	Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND). <i>World Journal of Urology</i> , 2022, 40, 349-354.	1.2	6
22	Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse. <i>World Journal of Urology</i> , 2019, 37, 2081-2090.	1.2	5
23	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. <i>European Urology Oncology</i> , 2022, 5, 285-295.	2.6	4
24	Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210868.	1.4	4
25	Surgical treatment of metastatic germ cell cancer. <i>Asian Journal of Urology</i> , 2021, 8, 155-160.	0.5	3
26	Treatment of clinical stage I non-seminoma. <i>Asian Journal of Urology</i> , 2021, 8, 161-169.	0.5	3
27	Late toxicities and recurrences in patients with clinical stage I nonseminomatous germ cell tumor after one cycle of adjuvant BEP versus primary retroperitoneal lymph node dissection: A 13-years follow-up analysis of a phase III trial cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5512-5512.	0.8	3
28	Evaluation of the oncologic benefit of adjunctive surgery at time of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).. <i>Journal of Clinical Oncology</i> , 2020, 38, 388-388.	0.8	3
29	Short-term and long-term outcomes after resection of thoracic growing teratoma syndrome. <i>World Journal of Urology</i> , 2021, 39, 2579-2585.	1.2	2
30	Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testis cancer in the salvage setting.. <i>Journal of Clinical Oncology</i> , 2019, 37, 524-524.	0.8	2
31	Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers. <i>Journal of Urology</i> , 2022, 207, 617-626.	0.2	2
32	Analysis of three models to predict pathohistology in patients undergoing postchemotherapy RPLND for (pcRPLND) advanced nonseminomatous germ cell tumors (NSGCT).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16053-e16053.	0.8	0
33	Validation of the two best models to predict –benign–pathohistology in patients with advanced nonseminomatous germ cell tumors (NSGCT) undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).. <i>Journal of Clinical Oncology</i> , 2020, 38, 389-389.	0.8	0
34	Multicenter analysis of serum tumor markers, treatment patterns, and relapse in patients with testicular cancer in clinical stage IS.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5052-5052.	0.8	0
35	Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 955-955.	0.2	0
36	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 302-302.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Need for organ preservation in postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).. Journal of Clinical Oncology, 2022, 40, 5031-5031.	0.8	0